Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...

The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Citi keeps a Buy rating on Incyte (INCY) with an $88 price target after the company presented data from its pivotal Phase 3 TRuE-PN1 trial ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been the company’s driving focus for years. Now, with Jakafi approaching ...

Despite the healthy growth, Incyte provided guidance for leading drugs, Jakafi and Opzelura, that were below expectations. Management expects sales of the hematology drug Jakafi to be between $2. ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis (PN). The data ...